David A. Siegel Enanta Pharmaceuticals Inc Transaction History

Two Sigma Advisers, LP

$41.3 Billion
Q3 2024

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Enanta Pharmaceuticals Inc stock. As of the latest transaction made, Two Sigma Advisers, LP holds 233,000 shares of ENTA stock, worth $1.4 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

233,000

Previous 232,800 0.09%

Holding current value

$1.4 Million

Previous $3.02 Million 19.97%

% of portfolio

0.01%

Previous 0.01%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$10.05 - $16.54 $2,010 - $3,308	200 Added 0.09%	233,000 $2.42 Million
Q2 2024 Aug 14, 2024	SELL	$11.43 - $17.02 $562,356 - $837,384	-49,200 Reduced 17.45%	232,800 $3.02 Million
Q1 2024 May 15, 2024	SELL	$10.08 - $17.46 $88,704 - $153,648	-8,800 Reduced 3.03%	282,000 $4.92 Million
Q4 2023 Feb 14, 2024	BUY	$8.18 - $10.78 $1.3 Million - $1.71 Million	158,400 Added 119.64%	290,800 $2.74 Million
Q3 2023 Nov 14, 2023	BUY	$11.09 - $22.13 $1.17 Million - $2.34 Million	105,900 Added 399.62%	132,400 $1.48 Million
Q2 2023 Aug 14, 2023	SELL	$20.68 - $39.85 $200,596 - $386,545	-9,700 Reduced 26.8%	26,500 $567,000
Q1 2023 May 15, 2023	SELL	$38.82 - $54.59 $791,928 - $1.11 Million	-20,400 Reduced 36.04%	36,200 $1.46 Million
Q4 2022 Feb 14, 2023	BUY	$40.77 - $53.73 $403,623 - $531,927	9,900 Added 21.2%	56,600 $2.63 Million
Q3 2022 Nov 14, 2022	SELL	$48.29 - $71.27 $526,361 - $776,843	-10,900 Reduced 18.92%	46,700 $2.42 Million
Q2 2022 Aug 15, 2022	SELL	$38.13 - $76.93 $91,512 - $184,632	-2,400 Reduced 4.0%	57,600 $2.72 Million
Q1 2022 May 16, 2022	SELL	$56.06 - $74.11 $2.13 Million - $2.82 Million	-38,000 Reduced 38.78%	60,000 $4.27 Million
Q4 2021 Feb 14, 2022	BUY	$60.19 - $97.37 $975,078 - $1.58 Million	16,200 Added 19.8%	98,000 $7.33 Million
Q3 2021 Nov 15, 2021	BUY	$41.02 - $58.65 $258,426 - $369,495	6,300 Added 8.34%	81,800 $4.65 Million
Q2 2021 Aug 16, 2021	SELL	$43.76 - $53.11 $218,800 - $265,550	-5,000 Reduced 6.21%	75,500 $3.32 Million
Q1 2021 May 17, 2021	SELL	$41.69 - $54.95 $429,407 - $565,985	-10,300 Reduced 11.34%	80,500 $3.97 Million
Q4 2020 Feb 16, 2021	BUY	$41.16 - $47.47 $465,107 - $536,411	11,300 Added 14.21%	90,800 $3.82 Million
Q3 2020 Nov 16, 2020	SELL	$43.36 - $53.53 $472,624 - $583,477	-10,900 Reduced 12.06%	79,500 $3.64 Million
Q2 2020 Aug 14, 2020	SELL	$46.37 - $57.58 $78,829 - $97,886	-1,700 Reduced 1.85%	90,400 $4.54 Million
Q1 2020 May 15, 2020	BUY	$40.22 - $62.0 $1.61 Million - $2.48 Million	40,000 Added 76.78%	92,100 $4.74 Million
Q4 2019 Feb 14, 2020	BUY	$57.95 - $66.61 $1.43 Million - $1.64 Million	24,600 Added 89.45%	52,100 $3.22 Million
Q3 2019 Nov 14, 2019	SELL	$60.08 - $88.17 $42,056 - $61,719	-700 Reduced 2.48%	27,500 $1.65 Million
Q2 2019 Aug 14, 2019	BUY	$81.3 - $97.35 $1.43 Million - $1.71 Million	17,600 Added 166.04%	28,200 $2.38 Million
Q4 2018 Feb 14, 2019	SELL	$65.41 - $84.65 $183,148 - $237,020	-2,800 Reduced 20.9%	10,600 $751,000
Q3 2018 Nov 14, 2018	SELL	$85.46 - $126.37 $2.92 Million - $4.32 Million	-34,200 Reduced 71.85%	13,400 $1.15 Million
Q2 2018 Aug 14, 2018	BUY	$81.85 - $120.51 $466,544 - $686,907	5,700 Added 13.6%	47,600 $5.52 Million
Q1 2018 May 15, 2018	BUY	$57.91 - $92.15 $509,607 - $810,920	8,800 Added 26.59%	41,900 $3.39 Million
Q4 2017 Feb 14, 2018	BUY	$45.65 - $59.37 $958,650 - $1.25 Million	21,000 Added 173.55%	33,100 $1.94 Million
Q3 2017 Nov 14, 2017	BUY	$37.91 - $46.8 $458,710 - $566,280	12,100	12,100 $566,000

Others Institutions Holding ENTA

# of Institutions

110

Shares Held

21.1M

Call Options Held

4.8K

Put Options Held

4.6K

View Full List

About ENANTA PHARMACEUTICALS INC

Ticker ENTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 20,724,900
Market Cap $125M
Description
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and li...

More about ENTA

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account